High CXCL6 drives matrix expression and correlate with markers of poor outcome in IPF

Signaling via G protein-coupled receptors (GPCRs) can modulate levels of cyclic adenosine monophosphate (cAMP) and shape the functions of fibroblasts in idiopathic pulmonary fibrosis (IPF). We have identified Chemokine (C-X-C) Motif Ligand 6 (CXCL6) as a potential pro-fibrotic GPCR ligand. We tested the function of CXCL6 in ex vivo human donor and fibrotic lung fibroblasts and in an animal model of pulmonary fibrosis. We also measured levels of CXCL6 in the blood and bronchoalveolar lavage (BAL) of patients with IPF. CXCL6 decreased cAMP levels in a dose-dependent manner in Donor and IPF Fibroblasts. CXCL6 mRNA and protein were localized to epithelial cells. Administration of mCXCL5 (LIX, murine CXCL6 homologue) to mice increased collagen synthesis with and without bleomycin. CXCL6 increased Collagen I and α-SMA levels in Donor and IPF Fibroblasts. Silencing of CXCR1/2 as well as Reparixin, a CXCR1/2 inhibitor, blocked effects of CXCL6. Treprostinil blocked effects of CXCL6 only on levels of α-SMA but not on Collagen I. CXCL6 levels in the BAL of two separate cohorts of patients with IPF was associated with poor survival. We conclude that high CXCL6 drives fibroblast function and correlates with poor outcomes in IPF.

[1]  G. Teng,et al.  Molecular mapping of interstitial lung disease reveals a phenotypically distinct senescent basal epithelial cell population , 2021, JCI insight.

[2]  X. Varelas,et al.  ZNF416 is a pivotal transcriptional regulator of fibroblast mechanoactivation , 2021, The Journal of cell biology.

[3]  R. Mallampalli,et al.  Transcriptional and Proteomic Characterization of Telomere-Induced Senescence in a Human Alveolar Epithelial Cell Line , 2021, Frontiers in Medicine.

[4]  M. Peters-Golden,et al.  Myofibroblast dedifferentiation proceeds via distinct transcriptomic and phenotypic transitions , 2021, JCI insight.

[5]  Michael R. Green,et al.  Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death. , 2021, Blood.

[6]  S. Nathan,et al.  Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. , 2021, The New England journal of medicine.

[7]  N. Kaminski,et al.  Macrophage-derived netrin-1 drives adrenergic nerve-associated lung fibrosis. , 2021, The Journal of clinical investigation.

[8]  A. Jegga,et al.  Inhibition of Aurora Kinase B attenuates fibroblast activation and pulmonary fibrosis , 2020, EMBO molecular medicine.

[9]  M. Rojas,et al.  Toll interacting protein protects bronchial epithelial cells from bleomycin‐induced apoptosis , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  D. Tschumperlin,et al.  Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma. , 2020, Pharmacology & therapeutics.

[11]  A. Haak,et al.  Targeting GPCR Signaling for Idiopathic Pulmonary Fibrosis Therapies. , 2020, Trends in pharmacological sciences.

[12]  B. Southern,et al.  Translocation of TRPV4-PI3Kγ complexes to the plasma membrane drives myofibroblast transdifferentiation , 2019, Science Signaling.

[13]  D. Tschumperlin,et al.  Urokinase Plasminogen Activator Overexpression Reverses Established Lung Fibrosis , 2019, Thrombosis and Haemostasis.

[14]  V. Shah,et al.  Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis , 2019, Science Translational Medicine.

[15]  Naftali Kaminski,et al.  Single Cell RNA-seq reveals ectopic and aberrant lung resident cell populations in Idiopathic Pulmonary Fibrosis , 2019, bioRxiv.

[16]  P. Benos,et al.  Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis , 2019, European Respiratory Journal.

[17]  O. Nayler,et al.  The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ , 2019, American journal of respiratory cell and molecular biology.

[18]  Steven K. Huang,et al.  “Yap”-ing about the Antifibrotic Benefits of Prostacyclin , 2019, American journal of respiratory cell and molecular biology.

[19]  G. Kayser,et al.  BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis , 2019, American journal of respiratory and critical care medicine.

[20]  A. Prasse,et al.  MicroRNA-144-3p targets relaxin/insulin-like family peptide receptor 1 (RXFP1) expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis , 2019, The Journal of Biological Chemistry.

[21]  X. Varelas,et al.  TGFβ-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repression , 2019, Journal of Cell Science.

[22]  S. Madala,et al.  New therapeutics based on emerging concepts in pulmonary fibrosis , 2018, Expert opinion on therapeutic targets.

[23]  T. Xie,et al.  RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation , 2018, Journal of Cell Science.

[24]  A. Letai,et al.  Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis , 2017, Science Translational Medicine.

[25]  C. Henke,et al.  IL-8 mediates idiopathic pulmonary fibrosis mesenchymal progenitor cell fibrogenicity , 2017, American journal of physiology. Lung cellular and molecular physiology.

[26]  M. Peters-Golden,et al.  Simultaneously Targeting Myofibroblast Contractility and Extracellular Matrix Cross‐Linking as a Therapeutic Concept in Airway Fibrosis , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  J. Tedrow,et al.  Loss of Twist1 in the Mesenchymal Compartment Promotes Increased Fibrosis in Experimental Lung Injury by Enhanced Expression of CXCL12 , 2017, The Journal of Immunology.

[28]  J. Tedrow,et al.  Expression of RXFP1 Is Decreased in Idiopathic Pulmonary Fibrosis. Implications for Relaxin-based Therapies. , 2016, American journal of respiratory and critical care medicine.

[29]  O. Eickelberg,et al.  Immune Mechanisms in Pulmonary Fibrosis. , 2016, American journal of respiratory cell and molecular biology.

[30]  Ying Huang,et al.  G-Protein-Coupled Lysophosphatidic Acid Receptors and Their Regulation of AKT Signaling , 2016, International journal of molecular sciences.

[31]  Jose D. Herazo-Maya,et al.  Integrative phenotyping framework (iPF): integrative clustering of multiple omics data identifies novel lung disease subphenotypes , 2015, BMC Genomics.

[32]  A. M. Houghton,et al.  Neutrophil elastase promotes myofibroblast differentiation in lung fibrosis , 2015, Journal of leukocyte biology.

[33]  Naftali Kaminski,et al.  A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis. , 2015, American journal of respiratory cell and molecular biology.

[34]  H. Binder,et al.  Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis , 2015, PloS one.

[35]  B. Southern,et al.  TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice. , 2014, The Journal of clinical investigation.

[36]  M. Teixeira,et al.  The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases , 2014, Expert review of clinical immunology.

[37]  C. Uyttenhove,et al.  CXCL6 antibody neutralization prevents lung inflammation and fibrosis in mice in the bleomycin model , 2013, Journal of leukocyte biology.

[38]  J. Chun,et al.  Lysophosphatidic acid receptor-2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice. , 2013, American journal of respiratory cell and molecular biology.

[39]  S. Rajagopal,et al.  Biased Agonism as a Mechanism for Differential Signaling by Chemokine Receptors* , 2013, The Journal of Biological Chemistry.

[40]  George C Tseng,et al.  Peripheral Blood Mononuclear Cell Gene Expression Profiles Predict Poor Outcome in Idiopathic Pulmonary Fibrosis , 2013, Science Translational Medicine.

[41]  D. Proud,et al.  Role of IL-17A and neutrophils in fibrosis in experimental hypersensitivity pneumonitis. , 2013, The Journal of allergy and clinical immunology.

[42]  B. Southern,et al.  FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis. , 2013, The American journal of pathology.

[43]  J. Chun,et al.  The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. , 2012, American journal of respiratory cell and molecular biology.

[44]  N. Kaminski,et al.  Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. , 2012, American journal of respiratory and critical care medicine.

[45]  A. Borczuk,et al.  Cytokine-like factor 1 gene expression is enriched in idiopathic pulmonary fibrosis and drives the accumulation of CD4+ T cells in murine lungs: evidence for an antifibrotic role in bleomycin injury. , 2012, The American journal of pathology.

[46]  T. Fukuda,et al.  A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice , 2012, European Respiratory Journal.

[47]  L. Barcelos,et al.  Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non‐competitive allosteric inhibitor , 2012, British journal of pharmacology.

[48]  Yong Zhou,et al.  Relaxin regulates myofibroblast contractility and protects against lung fibrosis. , 2011, The American journal of pathology.

[49]  Brian Bierie,et al.  Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. , 2011, The Journal of clinical investigation.

[50]  Hak Jung Kim,et al.  Activation of CXCR2 by extracellular matrix degradation product acetylated Pro-Gly-Pro has therapeutic effects against sepsis. , 2011, American journal of respiratory and critical care medicine.

[51]  S. Heymans,et al.  Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110γ. , 2011, Molecular cell.

[52]  E. White,et al.  Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. , 2010, The American journal of pathology.

[53]  G. Kayser,et al.  Essential role of osteopontin in smoking-related interstitial lung diseases. , 2009, The American journal of pathology.

[54]  M. Teixeira,et al.  Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary inflammation and fibrosis. , 2009, American journal of respiratory cell and molecular biology.

[55]  G. Raghu,et al.  Telomere shortening in familial and sporadic pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.

[56]  S. Wettlaufer,et al.  Prostaglandin E2 inhibits specific lung fibroblast functions via selective actions of PKA and Epac-1. , 2008, American journal of respiratory cell and molecular biology.

[57]  P. Lansdorp,et al.  Short telomeres are a risk factor for idiopathic pulmonary fibrosis , 2008, Proceedings of the National Academy of Sciences.

[58]  S. Raguz,et al.  Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence , 2008, Cell.

[59]  V. Lagente,et al.  Influence of early neutrophil depletion on MMPs/TIMP-1 balance in bleomycin-induced lung fibrosis. , 2007, International immunopharmacology.

[60]  A. Borczuk,et al.  Methionine aminopeptidase-2 as a selective target of myofibroblasts in pulmonary fibrosis. , 2007, American journal of respiratory cell and molecular biology.

[61]  D. Aronoff,et al.  Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[62]  Antje Prasse,et al.  A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. , 2006, American journal of respiratory and critical care medicine.

[63]  Wei Wu,et al.  Comparison of normalization methods for CodeLink Bioarray data , 2005, BMC Bioinformatics.

[64]  J. Pilewski,et al.  Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. , 2005, The American journal of pathology.

[65]  P. Insel,et al.  Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Pietro Ghezzi,et al.  Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[67]  S. Husson,et al.  Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. , 2003, European journal of biochemistry.

[68]  J. Pilewski,et al.  Pharmacological modulation of ion transport across wild-type and DeltaF508 CFTR-expressing human bronchial epithelia. , 2000, American journal of physiology. Cell physiology.

[69]  L. Moreland,et al.  Recombinant Human Relaxin in the Treatment of Scleroderma , 2000, Annals of Internal Medicine.

[70]  A. Zaslaver,et al.  GCP-2-induced internalization of IL-8 receptors: hierarchical relationships between GCP-2 and other ELR(+)-CXC chemokines and mechanisms regulating CXCR2 internalization and recycling. , 2000, Blood.

[71]  C. Browning,et al.  Signalling by CXC‐chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPγS binding induced by IL‐8 and GROα , 1999, British journal of pharmacology.

[72]  J. Fujita,et al.  The role of neutrophils in the pathogenesis of idiopathic pulmonary fibrosis. , 1997, Chest.

[73]  A. Morris,et al.  Regulation of effectors by G-protein alpha- and beta gamma-subunits. Recent insights from studies of the phospholipase c-beta isoenzymes. , 1997, Biochemical pharmacology.

[74]  S. Volinia,et al.  Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. , 1995, Science.

[75]  P. Ward,et al.  The development of bleomycin-induced pulmonary fibrosis in neutrophil-depleted and complement-depleted rats. , 1981, The American journal of pathology.

[76]  G. Raghu,et al.  American Thoracic Society Documents An Official American Thoracic Society Clinical Practice Guideline : The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease , 2012 .

[77]  K. Brown,et al.  Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. , 2008, Chest.

[78]  F. Martinez,et al.  Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia. , 2008, American journal of respiratory and critical care medicine.

[79]  J. Roes,et al.  Mice lacking neutrophil elastase are resistant to bleomycin-induced pulmonary fibrosis. , 2007, The American journal of pathology.

[80]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .